|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1,045 GBX | 0.00% |
|
-2.34% | +53.68% |
| Apr. 10 | 4basebio to supply synthetic DNA for mRNA vaccine program | AN |
| Apr. 10 | 4Basebio plc Announces the Supply of Its opDNA? DNA Products into Tier 1 Pharma Client's Vaccine Program | CI |
4basebio PLC reported earnings results for the half year ended June 30, 2022. For the half year, the company reported sales was GBP 0.152 million compared to GBP 0.179 million a year ago. Net loss was GBP 2.43 million compared to GBP 1.65 million a year ago.
Basic loss per share from continuing operations was GBP 0.2 compared to GBP 0.13 a year ago.
| 1st Jan change | Capi. | |
|---|---|---|
| +53.68% | 165M | |
| +1.97% | 42.11B | |
| +48.83% | 40.08B | |
| +8.15% | 40B | |
| -10.82% | 26.87B | |
| +7.37% | 24.58B | |
| -23.64% | 18.44B | |
| +2.07% | 11.94B | |
| +31.90% | 11.66B | |
| +7.44% | 11.01B |
4BASEBIO PLC 
